Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
NKG
Product ID:
C001316
Background:
NOD.Cg
Documents:
Click here to download >
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Model Name
NKG
Product ID
C001316
Gene Name
Il2rg
Background
NOD.Cg
Gene Alias
gc; p64; [g]c; CD132; gamma(c)
Classification
Immunodeficient Mouse Models
NCBI ID
16186
Phenotype
MGI:96551
Chromosome
X
More
Rare Disease Data Center >>
Document
Click here to download >>
Note
Note: When using this mouse strain in a publication, please cite “NKG mice (Catalog C001316) were purchased from Cyagen.”
Strain Description
NKG mice are a kind of severe immunodeficient mice generated by Cyagen by deleting the Il2rg gene from NOD-Scid genetic background mice. NKG mice exhibit deficiency of mature T cells, B cells, and functional NK cells, reduced complement activity, and weak phagocytosis of human-derived cells by macrophages, which are well suited for transplantation of human hematopoietic stem cells (HSC), peripheral blood mononuclear cells (PBMC), adult stem cells and tissues, and patient-derived xenograft (PDX).
Application Area
Area
Immune system and tumor immunity research
Area
Hematopoietic development and blood disorders research
Area
Infectious disease studies such as HIV and AIDS
Area
Tumor transplantation and anti-tumor efficacy studies
Area
CDX, PDX, GvHD, and humanized immune system (HIS) research
Validation Data
References
Acta Biomaterialia
Sep, 2023
PTT/ PDT-induced microbial apoptosis and wound healing depend on immune activation and macrophage phenotype transformation
Read More
BMC Cancer
Sep, 2022
MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells
Read More
Stem Cell Research
Dec, 2024
Human induced pluripotent stem cell line (FDHSi005-A) derived from a patient with a deep intronic variant in the GNE gene
Read More
Frontiers in Immunology
Jan, 2025
A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells
Read More
Cancer Immunology Research
Jan, 2023
Enhancing the Antitumor Immunity of T Cells by Engineering the Lipid-Regulatory Site of the TCR/CD3 Complex
Read More
预印本
Mar, 2023
Extensive Dysregulation of SLK Splicing in Cancers Impacts Metastasis
Read More
International Journal of Nanomedicine
Oct, 2023
The Therapeutic Effects of MUC1-C shRNA@Fe3O4 Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer
Read More
Heliyon
Jan, 2024
The construction, validation and promotion of the nomogram prognosis prediction model of UCEC, and the experimental verification of the expression and knockdown of the key gene GPX4
Read More
ACS Materials Letters
Aug, 2024
Bacterial Programmed Cell Death Induced by Nanotherapeutic Strategies
Read More
Molecular Therapy
Feb, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
Read More
Signal Transduction and Targeted Therapy
Jun, 2024
Engineered extracellular vesicles for targeted reprogramming of cancer-associated fibroblasts to potentiate therapy of pancreatic cancer
Read More
Discover Oncology
Apr, 2024
Cyclovirobuxine D inhibits hepatocellular carcinoma growth by inducing ferroptosis of hepatocellular carcinoma cells
Read More
International Journal of Biological Sciences
Jan, 2025
SERINC2-mediated serine metabolism promotes cervical cancer progression and drives T cell exhaustion
Read More
Cancers
Dec, 2022
Role of Epidermal Growth Factor Receptor-Specific CAR-T Cells in the Suppression of Esophageal Squamous Cell Carcinoma
Read More
Journal of Translational Medicine
Feb, 2024
Combined therapy of CAR-IL-15/IL-15Rα-T cells and GLIPR1 knockdown in cancer cells enhanced anti-tumor effect against gastric cancer
Read More
Taylor & Francis
Oct, 2024
Anti-HER2 biparatopic antibody KJ015 has near-native structure, functional balanced high affinity, and synergistic efficacy with anti-PD-1 treatment in vivo
Read More
MedComm
Oct, 2024
Feedback loop LINC00511–YTHDF2–SOX2 regulatory network drives cholangiocarcinoma progression and stemness
Read More
Microbial Cell Factories
May, 2023
Manufacture and evaluation of a HER2-positive breast cancer immunotoxin 4D5Fv-PE25
Read More
Pharmacological Research
Sep, 2024
Developing patient-derived organoids to demonstrate JX24120 inhibits SAMe synthesis in endometrial cancer by targeting MAT2B
Read More
The EMBO Journal
Jan, 2025
Micropeptide hSPAR regulates glutamine levels and suppresses mammary tumor growth via a TRIM21-P27KIP1-mTOR axis
Read More
ACS Pharmacology & Translational Science
Nov, 2024
Gallium-68 Labeled Positron Emission Computed Tomography Tracer Targeting Glypican-3 with High Contrast for Hepatocellular Carcinoma Imaging
Read More
Materials Today Bio
Jun, 2024
Enhancing glioma-specific drug delivery through self-assembly of macrophage membrane and targeted polymer assisted by low-frequency ultrasound irradiation
Read More
Nature Communications
Oct, 2024
Iron-loaded cancer-associated fibroblasts induce immunosuppression in prostate cancer
Read More
British Journal of Haematology
Jul, 2024
Development of novel humanized CD19/BAFFR bicistronic chimeric antigen receptor T cells with potent antitumor activity against B-cell lineage neoplasms
Read More
PLoS ONE
Sep, 2024
TFAB002s, novel CD20-targeting T cell-dependent bispecific Fab-FabCH3 antibodies, exhibit potent antitumor efficacy against malignant B-cell lymphoma
Read More
Advanced Science
Jan, 2025
A Novel 167-Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination
Read More
Nature Communications
Dec, 2024
An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control
Read More
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research